Search results
Results from the WOW.Com Content Network
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share increased 28.16% over the past ...
Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. [3] OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. [4]
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Mutations are associated with numerous medical conditions including abnormal bone development (e.g. craniosynostosis syndromes) and cancer. Five Prime has a monoclonal antibody, FPA144, in early stage trials, that targets FGFR2b (a form of FGFR2), to treat gastric tumours that overexpress FGFR2b, by preventing binding of certain FGFs to FGFR2b ...
Revenue would be up 1.87% on a year-over-year basis. Five Prime Therapeutics's reported EPS has stacked up against analyst estimates in the past like this: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 ...